Registro de fonte primária
A FDA definiu a data PDUFA para a NDA do tebipenem HBr para 18 de junho de 2026. A NDA foi submetida pela GSK em dezembro de 2025 e é suportada pelo ensaio de Fase 3 PIVOT-PO, que foi interrompido precocemente por eficácia em maio de 2025.
EX-99.1 2 d147628dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update • New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 • Spero maintains its cash runway guidance into 2028 CAMBRIDGE, Mass., May 13, 2026 — Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make solid progress on the tebipenem HBr program al